The process of discovery and development of a molecule is complex, long and costly. Before making a decision on the offer that best meets your needs, we offer online scientific resources and our latest news to help you get to know us better. Our experts are also at your disposal to help and support you in your research and development program.

Filter by BU or service
  • All
  • Corporate
  • Service
  • Biotech
  • A.I
  • Homing program
  • Financial
  • HR
Filter by BU or service
Filter by category
  • All
  • Webinar
  • Posters
  • Scientific publications
  • Press release
  • Press coverage
  • Media kit
  • News
Filter by category
loader

Scientific resources

Webinar

Oncology Webinar
Service
05/04/2022

[EN] How to Better Optimize an Oncology Drug Discovery Program

Watch this oncology webinar on preclinical pharmacology, covering all step of the drug discovery journey from target validation to clinical studies...

Service
07/12/2021

[EN] Preclinical Models for Microbiome Research in Oncology and Inflammatory Diseases

Learn how current in vivo preclinical models meet the needs of microbiome research and innovation while outlining their limitations and the challenges still to be overcome in this growing field.

Service
16/11/2021

[EN] How Rodent and NHP Models Support COVID-19 Treatment Development

Learn how to select the most appropriate COVID-19 animal model for preclinical studies in this webinar

WebinarMRT_website_newspage
Service
05/11/2021

[EN] Establishing an Expert Network for Your Radiopharmaceutical Drug Development Program

Learn how the DRIVE-MRT solution enables the rationalization, design & optimization of targeted & effective radiopharmaceuticals against specific cancers.

There are no resources available for your request. Contact us directly via our contact form for any information request

Posters

Scientific Resources | Oncodesign
Service
28/03/2022

Scientific Posters | AACR 2022

Find all 4 posters that are presented during AACR 2022. They unveil our expertise in oncology using our scientific know-how (medicinal chemistry, radio-imaging, in vivo model and microbiome)

Service
27/09/2021

Structure-Based Design of small macrocyclic CDK9 degraders as chemical biology tools and beyond

With small macrocyclic “probes” from our proprietary library in the low nanomolar range IC50, we turned our attention to CDK9 inhibitors with good selectivity profile against CDK1/2/5/7 as a starting point for building bifunctional small macrocyclic kinase degraders.

Service
26/08/2021

Discovery of Novel Inhibitors of PIM-1 Kinase Enabled by Generative AI

Use generative AI to generate and identify new PIM-1 kinase inhibitor hits with activity, freedom-to-operate, and good in vitro ADME properties.

Biotech
01/09/2020

NANOCYCLIX® ALK2 INHIBITORS TO OVERCOME CANCER INDUCED ANEMIA

NANOCYCLIX® ALK2 INHIBITORS TO OVERCOME CANCER INDUCED ANEMIA

Biotech
31/03/2019

Nanocyclix: next generation kinase therapeutics A chemocentric approach for the discovery of selective kinase inhibitors

Nanocyclix: next generation kinase therapeuticsA chemocentric approach for the discovery of selective kinase inhibitors

There are no resources available for your request. Contact us directly via our contact form for any information request

Scientific publications

Service
18/02/2022

Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity

Published in Science Advances: the preclinical development program of exoASO-STAT6, a novel, engineered #exosome precision medicine candidate for the treatment of macrophage-rich tumors.

A.I
06/01/2022

OncoSNIPE® Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients

Early/ late resistance marker; Immunological profile; NGS; Non small-cell lung cancer; Pancreatic ductal adenocarcinoma; Triple negative breast or Luminal Breast Cancer.

Service
11/12/2021

Synergistic Interferon-Alpha-Based Combinations for Treatment of SARS-CoV-2 and Other Viral Infections

SARS-CoV-2; antiviral drug combination; hepatitis C virus; hepatitis E virus; human immunodeficiency virus; influenza A virus; interferon-alpha.

Service
04/09/2021

Nafamostat–Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2

SARS-CoV-2; interferon-alpha; nafamostat; antiviral drug combination; broad-spectrum antivirals

Service
04/09/2021

Nafamostat-Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2

SARS-CoV-2; antiviral drug combination; broad-spectrum antivirals; interferon-alpha; nafamostat.

Biotech
12/06/2021

Inhibiting Endothelial Cell Function in Normal and Tumor Angiogenesis Using BMP Type I Receptor Macrocyclic Kinase Inhibitors

Inhibiting Endothelial Cell Function in Normal and Tumor Angiogenesis Using BMP Type I Receptor Macrocyclic Kinase Inhibitors

Biotech
07/10/2019

Development of Macrocycle Kinase Inhibitors for ALK2 Using Fibrodysplasia Ossificans Progressiva-Derived Endothelial Cells

Development of Macrocycle Kinase Inhibitors for ALK2 Using Fibrodysplasia Ossificans Progressiva-Derived Endothelial Cells

Biotech
24/10/2014

In vivo inhibition of RIPK2 kinase alleviates inflammatory disease

In vivo inhibition of RIPK2 kinase alleviates inflammatory disease

There are no resources available for your request. Contact us directly via our contact form for any information request

Press

Press release

investors-oncodesign
Corporate
Financial
07/04/2022

Oncodesign confirms its very good results in 2021 and an attractive outlook for 2022

Read the full press release about our very good results in 2021 & an attractive outlook for 2022 for the group & our BUs Service, Biotech & AI.

investors-oncodesign
Corporate
Financial
07/04/2022

Oncodesign confirms its very good results in 2021 and an attractive outlook for 2022

Read the full press release about our very good results in 2021 & an attractive outlook for 2022 for the group & our BUs Service, Biotech & AI.

Drive-Biologics - Discovery & Developement | Oncodesign
Service
24/02/2022

Abzena, Alira Health and Oncodesign launch DRIVE-Biologics to support access to specialist services

Abzena x Alira Health x Oncodesign: unveil unique integrated solution with specialist services, from biologics discovery to clinical & commercial manufacturing

Nanocyclix portfolio - R&D pipeline
Biotech
Financial
08/02/2022

SEngine Precision Medicine & Oncodesign Announce Collaboration Agreement for the Discovery of New Personalized Cancer Treatment

Read all the details of the collaboration agreement for R&D of a new personalized cancer treatment for aggressive and untreatable tumors.

Nanocyclix portfolio - R&D pipeline
Biotech
Financial
08/02/2022

SEngine Precision Medicine & Oncodesign Announce Collaboration Agreement for the Discovery of New Personalized Cancer Treatment

Read all the details of the collaboration agreement for R&D of a new personalized cancer treatment for aggressive and untreatable tumors.

Financial Result oncodesign
Corporate
Financial
27/01/2022

Oncodesign announces a 2021 turnover of €31.3M, up by 22%, and expects to break even

Find all the 2021 financial information: 2021 turnover of €31.3M, up by 22%, and expects to break even and dive into the BU financial results

Financial Result oncodesign
Corporate
Financial
27/01/2022

Oncodesign announces a 2021 turnover of €31.3M, up by 22%, and expects to break even

Find all the 2021 financial information: 2021 turnover of €31.3M, up by 22%, and expects to break even and dive into the BU financial results

Financial Agenda for 2022 - Oncodesign
Corporate
Financial
05/01/2022

ONCODESIGN announces its 2022 financial agenda

Oncodesign announces all the regulatory dates as far as financial information is concerned. Let's have a look :)

Financial Agenda for 2022 - Oncodesign
Corporate
Financial
05/01/2022

ONCODESIGN announces its 2022 financial agenda

Oncodesign announces all the regulatory dates as far as financial information is concerned. Let's have a look :)

A molecule in the active site of RIPK2
Biotech
04/11/2021

ONCODESIGN strengthens the intellectual property of ODS 101 in treating inflammatory bowel disease

Protection of RIPK2 inhibitors resulting from Nanocyclix® technology with patents granted on the main international markets: Europe, United States, Japan and Eurasia

Oncodesign x TiumBio signed a collaboration agreement | Fibrosis
Biotech
21/10/2021

Oncodesign and TiumBio sign collaboration agreement for R&D of fibrosis drug candidates

Under this agreement, Oncodesign will be responsible for identification, chemical synthesis & optimization of Nanocyclix® drug candidates & their early-stage analysis. TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates.

SOLO - Pharmaco-Imaging | Preclinical Imaging Services | Oncodesign
Service
01/07/2021

Oncodesign, Covalab, CheMatech and ABX-CRO launch DRIVE™-MRT

Discover the alliance of experts in radiopharmaceuticals: an innovative offer in therapeutic development in nuclear medicine from the validation of therapeutic targets, the generation of radiolabeled biological vectors, the optimization of leads, the generation of drug candidates to IND, the design and management of clinical trials.

SOLO - Pharmaco-Imaging | Preclinical Imaging Services | Oncodesign
Service
Financial
28/06/2021

Oncodesign launches its new DRIVE-MRT™ service offer in partnership with Covalab, CheMatech and ABX-CRO

[Press Release] Explore our brand new service offer DRIVE-MRT. it allows the rationalization, design and optimization of targeted radiopharmaceutical products that are effective against certain metastatic cancers.

A.I
Financial
18/05/2021

InterSystems & Oncodesign partner for the optimization of data use to enhance and accelerate Drug Discovery processes in oncology

Read PRess Release to have an insight on how to organize & leverage healthcare data to accelerate the search for new treatments in oncology using AI.

Corporate
A.I
18/09/2018

Precision medicine: Cap Digital and Medicen Paris-Region team-up with Oncodesign, Servier and Intersystems on Hu-PreciMED

Hu-PreciMED project will gear French precision medicine industry towards discovering new diagnostic approaches & novel therapeutic treatments.

There are no resources available for your request. Contact us directly via our contact form for any information request

Press coverage

There are no resources available for your request. Contact us directly via our contact form for any information request

Media kit

Corporate

MEDIA KIT

Find all the media information of Oncodesign, logo, boiler plate, photos, press contacts

There are no resources available for your request. Contact us directly via our contact form for any information request

News

Artificial Intelligence Conferences | Oncodesign
A.I
28/04/2022

Places to meet and engage conversation with our experts in AI and Drug Discovery

Come back regularly to check if there is a meeting nearby your place to meet one of our experts in both AI & Drug Discovery.

Meet Oncodesign in person this spring
Corporate
Service
27/04/2022

[Congress] Meet Oncodesign in person this spring

Check out where to meet Oncodesign this spring... surely we can arrange a meeting somewhere.

Parkinson's disease | Oncodesign
Biotech
11/04/2022

Parkinson’s Disease: Growing Prevalence And Continued Significant Medical Need

Explore the disease & find out about our strategic R&D collaboration with Servier: info, press releases & video!

investors-oncodesign
Corporate
Financial
07/04/2022

Oncodesign confirms its very good results in 2021 and an attractive outlook for 2022

Read the full press release about our very good results in 2021 & an attractive outlook for 2022 for the group & our BUs Service, Biotech & AI.

Scientific Resources | Oncodesign
Service
28/03/2022

Scientific Posters | AACR 2022

Find all 4 posters that are presented during AACR 2022. They unveil our expertise in oncology using our scientific know-how (medicinal chemistry, radio-imaging, in vivo model and microbiome)

[CONGRESS] Microbiome & Probiotics
Service
18/03/2022

[Congress] AACR Annual Meeting | 8-13 April 2022

Meet us in person at the Annual Meeting of the AACR in New Orleans!

Oncology Webinar
Service
16/03/2022

[Webinar] How to better optimize an oncology drug discovery program

Register for this webinar discussing how conventional and innovative integrated technological skills should be incorporated into an oncology program.

[CONGRESS] Microbiome & Probiotics
Service
14/03/2022

[CONGRESS] Microbiome & Probiotics, 29-30 March 2022

Meet us at the Microbiome & Probiotics congress in San Diego | March 2022. Explore our expertise in assessing the role of microbiome in drug discovery

Drive-Biologics - Discovery & Developement | Oncodesign
Service
24/02/2022

Abzena, Alira Health and Oncodesign launch DRIVE-Biologics to support access to specialist services

Abzena x Alira Health x Oncodesign: unveil unique integrated solution with specialist services, from biologics discovery to clinical & commercial manufacturing

Nanocyclix portfolio - R&D pipeline
Biotech
Financial
08/02/2022

SEngine Precision Medicine & Oncodesign Announce Collaboration Agreement for the Discovery of New Personalized Cancer Treatment

Read all the details of the collaboration agreement for R&D of a new personalized cancer treatment for aggressive and untreatable tumors.

Financial Result oncodesign
Corporate
Financial
27/01/2022

Oncodesign announces a 2021 turnover of €31.3M, up by 22%, and expects to break even

Find all the 2021 financial information: 2021 turnover of €31.3M, up by 22%, and expects to break even and dive into the BU financial results

Service
14/01/2022

[Congress] Microbiome Movement Drug Development

Oncodesign will be at the digital event Microbiome Movement Drug Development. Take the opportunity to learn more about SOLO Microbiome.

Financial Agenda for 2022 - Oncodesign
Corporate
Financial
05/01/2022

ONCODESIGN announces its 2022 financial agenda

Oncodesign announces all the regulatory dates as far as financial information is concerned. Let's have a look :)

Nanocyclix portfolio - R&D pipeline
Biotech
23/11/2021

Biotech Show Case: looking for partners to pursue the development of our Nanocyclix® technology products together!

Meet Dr. Jan Hoflack during Biotech ShowCase to explore our products pipeline using our technological module Nanocyclix®.

A molecule in the active site of RIPK2
Biotech
04/11/2021

ONCODESIGN strengthens the intellectual property of ODS 101 in treating inflammatory bowel disease

Protection of RIPK2 inhibitors resulting from Nanocyclix® technology with patents granted on the main international markets: Europe, United States, Japan and Eurasia

EHDEN - The European Health Data & Evidence Network - Oncodesign
Corporate
A.I
28/10/2021

Oncodesign: EHDEN Certified SME

EHDEN network will enable transparent & fully reproducible research by standardizing both the health data & the analytical pipeline.

Karine Lignel | Senior Executive Vice President - Group Chief Development Officer - Oncodesign
Corporate
Financial
25/10/2021

Oncodesign has appointed Karine Lignel as Group Chief Development Officer

Oncodesign adds a new high-level competence to its COMEX to achieve its external growth objectives with Karine Lignel.

Oncodesign x TiumBio signed a collaboration agreement | Fibrosis
Biotech
21/10/2021

Oncodesign and TiumBio sign collaboration agreement for R&D of fibrosis drug candidates

Under this agreement, Oncodesign will be responsible for identification, chemical synthesis & optimization of Nanocyclix® drug candidates & their early-stage analysis. TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates.

Service
20/10/2021

[WEBINARS] Pharmaco-imaging, COVID-19, Microbiome…

[Webinars] Radiopharmaceutics, COVID-19, Microbiome… join us this fall during a webinar

Service
19/10/2021

[CONGRESS] Discovery UK: 26 – 27 October 2021

Oncodesign will be at the in-person event by Oxford Global in London, Discovery UK.

Financial Press Release | Oncodesign
Financial
16/09/2021

Oncodesign announces its results for the first half of 2021

Read all the financial information of Oncodesign and its Business Units Service, Biotech and Artificial Intelligence.

Corporate
Financial
05/07/2021

Oncodesign announces the appointment of Aline Aubertin as an independent director of the Board of Directors

Oncodesign strenghens its Board by appointing Aline Aubertin as new independent director.

Corporate
02/07/2021

Find out how we built our logo!

Oncodesign Find out how we built our logo! trajectory DNA innovation...green and bleue pharma colors Find out how we built our logo!

Corporate
01/07/2021

Brand new logo for Oncodesign

Brand new logo for Oncodesign. New graphic identity with evolutive look & feel approach... First element of our new logo.

Biotech
Financial
24/06/2021

Oncodesign provides an update on its progress on RIPK2

[Press Release] Find the update of the RIPK2 program and the start of new programs associated with Nanocyclix.

ressources-oncodesign
Service
23/06/2021

[Congress] Microbiome movement Drug Development Summit June 29 – July 1, 2021

Listen to our expert talk about “preclinical solutions for microbiome investigation in pathological situation and drug development”

Nanocyclix portfolio - R&D pipeline
Biotech
14/06/2021

Parkinson’s disease: Servier x Oncodesign announce the selection of a preclinical candidate

Read Press Release the selection of a preclinical candidate resulting from their strategic collaboration to find new treatments for Parkinson’s disease.

A.I
Financial
18/05/2021

InterSystems & Oncodesign partner for the optimization of data use to enhance and accelerate Drug Discovery processes in oncology

Read PRess Release to have an insight on how to organize & leverage healthcare data to accelerate the search for new treatments in oncology using AI.

Service
07/10/2019

[EN] [Congress] Start.Smart.Global 2019 – 7-10 October 2019: Roadshow in Japan & November 2019: Roadshow in South Korea

RoadShow in Japan and South Korean to demonstrate the potency and specificity of our innovative technology module Nanocyclix®

Corporate

Our brand Oncodesign

Our brand Oncodesign . Combination of the words oncology and design... Precision Medicine for patient... Oncodesign

There are no resources available for your request. Contact us directly via our contact form for any information request